Media Relations News Releases Year: - Any -2019201820172016 Items per page 102550 Dec 6, 2019 Summary ToggleNovartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy Nov 17, 2019 Summary ToggleNovartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF Nov 15, 2019 Summary ToggleNovartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) Oct 8, 2019 Summary ToggleNovartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept Oct 1, 2019 Summary ToggleNovartis and Microsoft announce collaboration to transform medicine with artificial intelligence Sep 29, 2019 Summary ToggleNovartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients Sep 1, 2019 Summary ToggleNovartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint Jul 1, 2019 Summary ToggleNovartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies Jul 1, 2019 Summary ToggleNovartis data underpin long-term efficacy of Aimovig® where other treatments have failed Jun 3, 2019 Summary ToggleXolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
